Important Information for Investors: Securities Class Action Lawsuit against Viatris Inc.
Kahn Swick & Foti, LLC (KSF) and its partner, former Attorney General of Louisiana, Charles C. Foti, Jr., are urging investors who purchased securities of Viatris Inc. (Viatris or the Company) between August 8, 2024, and February 26, 2025, inclusive (the “Class Period”), to take note of the following announcement:
Class Action Lawsuit against Viatris Inc.
KSF and Mr. Foti remind investors that they have until June 3, 2025, to file lead plaintiff applications in a securities class action lawsuit against Viatris. The complaint alleges that the Company and certain of its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material information during the Class Period, which caused investors harm.
Background
Viatris is a global healthcare company that was formed through the merger of Pfizer Inc.’s Upjohn business and Mylan N.V. The merger was completed on October 1, 2020. The Company focuses on developing, manufacturing, and marketing a broad portfolio of pharmaceutical and healthcare products.
Allegations
The class action lawsuit alleges that during the Class Period, Viatris and its executives made false and/or misleading statements and/or failed to disclose material information regarding:
- The Company’s financial results, including revenue and earnings
- The Company’s regulatory compliance and regulatory risks
- The Company’s business strategies and prospects
Effects on Individual Investors
If you purchased Viatris securities during the Class Period and suffered a loss, you may be eligible to recover your loss through the class action lawsuit. To learn more, you can contact KSF at 1-877-515-1850 or via email at [email protected].
Effects on the World
The outcome of this class action lawsuit could have significant implications for the pharmaceutical industry and the broader investment community. If the allegations are proven true, it could lead to increased scrutiny of other healthcare companies and their financial reporting practices. Additionally, it could result in significant damages being paid to affected investors.
Conclusion
Investors who purchased Viatris securities during the Class Period are encouraged to contact KSF to learn more about their potential eligibility to recover their losses. The deadline to file a lead plaintiff application is June 3, 2025. For more information, visit
This information is for informational purposes only and should not be considered legal or financial advice. KSF makes no representation as to the accuracy or completeness of any information on this site or found by following any link on this site. KSF is not associated with Viatris and is not affiliated with them in any way.
